Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 4;161(7):1670–1681. doi: 10.1097/j.pain.0000000000001858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 3. — Prophylactic effect of Ab181 on maxadilan-induced increase in DBF in rats 48 hours after drug treatment. Rats were given intravenous bolus injection of Ab181 (0.1, 0.3, 1, and 10 mg/kg, n = 6-7 rats/group). Forty-eight hours later, after obtaining a postdrug baseline (BL), maxadilan at a dose of 10 ng (in 20-µL DPBS) was injected intradermally. The dermal blood flow (DBF) was measured by a laser Doppler imager. (A) The increase in DBF (change from BL) caused by maxadilan injection over 60 minutes was expressed as % change from BL = [100 × (individual postmaxadilan flux − individual BL flux)/individual BL flux]. (B) % change from BL (left-axis) vs resulting serum concentrations (right axis) at 15 minutes after maxadilan; solid triangle represents % change from BL at 48 hours after drug treatment (left axis, mean ± SEM), and open bar represents serum concentration at 48 hours after drug treatment (right axis, mean ± SD). ***P < 0.001, ****P < 0.0001 compared with vehicle-treated group by one-way ANOVA followed by Dunnett's MCT. ANOVA, analysis of variance; DBPS, Dulbecco's phosphate-buffered saline; MCT, multiple comparison test.